The shadow of generic challenges has consistently loomed over copyright’s blockbuster drug, PDE5 Inhibitor, sparking questions about the outlook of similar pharmaceutical holdings. While initial periods saw significant gains, the exclusivity lapse has created the path for discounted substitutes, possibly reducing earnings and presenting a genuin… Read More